Analysis of changes in serum levels of endothelin-1 in patients with retinal vein occlusion
- Authors: Shelankova AV1, Budzinskaya MV1, Plyukhova AA1, Mikhaylova MA1, Nurieva NM2
-
Affiliations:
- Scientific Research Institute of Eye Diseases
- National Cеntrе for Oрhthalmology namеd aftеr Acadеmician Zarifa Aliyеva
- Issue: Vol 98, No 3 (2017)
- Pages: 409-412
- Section: New technologies in ophthalmology
- URL: https://ogarev-online.ru/kazanmedj/article/view/6493
- DOI: https://doi.org/10.17750/KMJ2017-409
- ID: 6493
Cite item
Full Text
Abstract
Aim. To analyze the level of endothelin-1 in blood serum in patients with retinal venous occlusions. Metods. 60 patients with macular edema due to retinal vein occlusion (RVO) were included in the study. 19 patients were diagnosed with central retinal vein occlusion, 9 of them had non-ischemic type and 10 had ischemic type of central retinal vein occlusion. 41 patients had branch retinal vein occlusion, 23 of them had non-ischemic type and 18 had ischemic type of occlusion. Patients underwent fluorescein angiography and optical coherence tomography fundus imaging. Before intravitreal injection of ranibizumab, the level of endothelin-1 in the blood serum was determined. Analysis was performed in patients’ subgroups depending on the localization of occlusion, type of occlusion, disease relapse, presence of optic disc swelling.
Results. Differences in the systemic level of endothelin-1, depending on the localization of occlusion, presence of ischemic type and relapse, the disease was not detected (p ≥0.05). With the development of optic disc swelling, a statistically significant increase in the level of endothelin-1 was noted in peripheral blood: 38.73 fmol/ml in patients with optic disc swelling and 27.65 fmol/ml in patients without it (p=0.018).
Conclusion. In patients with optic disc swelling a statistically significant increase of endothelin-1 in blood was revealed.
About the authors
A V Shelankova
Scientific Research Institute of Eye Diseases
Author for correspondence.
Email: shelankova_aleks@mail.ru
Moscow, Russia
M V Budzinskaya
Scientific Research Institute of Eye Diseases
Email: shelankova_aleks@mail.ru
Moscow, Russia
A A Plyukhova
Scientific Research Institute of Eye Diseases
Email: shelankova_aleks@mail.ru
Moscow, Russia
M A Mikhaylova
Scientific Research Institute of Eye Diseases
Email: shelankova_aleks@mail.ru
Moscow, Russia
N M Nurieva
National Cеntrе for Oрhthalmology namеd aftеr Acadеmician Zarifa Aliyеva
Email: shelankova_aleks@mail.ru
Baku, Azеrbaijan
References
- Hayreh S.S., Zimmerman M.B., Podhajsky P.А. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am. J. Ophthalmol. 1994; (117): 429-441.
- Михайлова М.А., Сизова М.В., Шеланкова А.В. Патогенез ретинальных венозных окклюзий. Вестн. офтальмол. 2014; 130 (2): 88-92.
- Hayreh S.S. Pathogenesis of occlusion of the central retinal vessels. Am. J. Ophthalmol. 1971; (72): 998-1011. doi: 10.1016/0002-9394(71)91706-5.
- Rogers S.L., McIntosh R.L., Lim L. et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010; (117): 1094-1101. doi: 10.1016/j.ophtha.2010.01.058.
- Ponto K.A., Elbaz H., Peto T. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. Wild. J. Thromb. Haemost. 2015 (13): 1254-1263. doi: 10.1111/jth.12982.
- Будзинская М.В., Михайлова М.А., Плюхова А.А. и др. Роль липидного обмена и изменений антиоксидантной системы в развитии ретинальных венозных окклюзий. Вестн. офтальмол. 2014; 130 (3): 3-8.
- Yanagisawa M. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; (332): 411-415. doi: 10.1038/332411a0.
- Loesch A. Perivascular nerves and vascular endothelium: recent advances. Histol. Histopathol. 2002; (17): 591-597.
- Faller D.V. Endothelial cell responses to hypoxic stress. Clin. Exp. Pharmacol. Physiol. 1999; (26): 74-84. doi: 10.1046/j.1440-1681.1999.02992.x.
- Campochiaro P.A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 2015; (49): 67-81. doi: 10.1016/j.preteyeres.2015.06.002.
- Vinores S.A., Youssri A.I., Luna J.D. et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 1997; (12): 99-109.
- Campochiaro P.A., Hafiz G., Shah S.M. et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol. Ther. 2008; (16): 791-799. doi: 10.1038/mt.2008.10.
- Шеланкова А.В., Михайлова М.А., Андреева И.В. и др. Эффективность антиангиогенной терапии у пациентов с макулярным отёком вследствие окклюзии центральной вены сетчатки. Соврем. технол. в офтальмол. 2015; (3): 184-186.
- Kida T., Flammer J., Oku H. et al. Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision. EPMA J. 2016; 7 (1): 18. doi: 10.1186/s13167-016-0066-2.
- Stangos A.N., Petropoulos I.K., Pournaras J.A. et al. The vasodilatory effect of juxta-arteriolar microinjection of endothelin: A receptor inhibitor in healthy and acute branch retinal vein occlusion minipig retinas. Invest. Ophthalmol. Vis. Sci. 2010; 51: 2185-2190. doi: 10.1167/iovs.09-3735.
- Salvatore S., Vingolo E.M. Endothelin-1 role in human eye: a review. J. Ophthalmol. 2010; 2010: 354645. Pub. online 2011 Mar. 3. doi: 10.1155/2010/354645.
Supplementary files
